Dupilumab in Adults and Adolescents with Eosinophilic EsophagitisEvan S. Dellon, Arsalan Shabbir, Marc E. Rothenberg et al.|New England Journal of Medicine|2022Cited by 452
Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil CountsSurya P. Bhatt, Raolat M. Abdulai, Klaus F. Rabe et al.|New England Journal of Medicine|2023Cited by 452
A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trialMichael Boyle, David M. Rodman, Scott C. Bell et al.|The Lancet Respiratory Medicine|2014Cited by 442
Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trialAmy S. Paller, Brad Shumel, Neil M.H. Graham et al.|Journal of the American Academy of Dermatology|2020Cited by 385
Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 InflammationSurya P. Bhatt, Lacey B. Robinson, Klaus F. Rabe et al.|New England Journal of Medicine|2024Cited by 240